Brief: Lantern Pharma Receives Regulatory Approval To Expand Harmonic Clinical Trial For Non-Small Cell Lung Cancer
22/04/2024 13:52
April 22 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA RECEIVES REGULATORY APPROVAL TO EXPAND
HARMONIC™
CLINICAL TRIAL FOR NON-SMALL CELL LUNG CANCER IN NEVER-SMOKERS
INTO JAPAN AND TAIWAN
Source text for Eikon: ID:nBw8nXL4Pa
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview